
ImmunoGen (IMGN) Stock Forecast & Price Target
ImmunoGen (IMGN) Analyst Ratings
Bulls say
Immunogen is a promising biotechnology company with a strong focus on antibody-drug conjugate (ADC) technology, which has shown great potential in delivering targeted cancer treatments. With a pipeline of three additional ADCs and upcoming ASH data as a key catalyst, Immunogen is poised for success in the near future. While there are risks involved, the company's partnerships and deep pipeline make it a sound investment option for those with a positive outlook.
Bears say
Immunogen is currently rated as Neutral, with a 12-month price target of $31.26 due to its recent cash acquisition by AbbVie. The target price is based on a SOTP analysis with a 6.5% WACC, primarily driven by NPV of mirvetuximab soravtansine cash flows through 2038, and near-term catalysts include Phase 1 updates for IMGC936 and Pivekimab triplet data in December 2023.
This aggregate rating is based on analysts' research of ImmunoGen and is not a guaranteed prediction by Public.com or investment advice.
ImmunoGen (IMGN) Analyst Forecast & Price Prediction
Start investing in ImmunoGen (IMGN)
Order type
Buy in
Order amount
Est. shares
0 shares